Tyra Biosciences (TYRA) Investor Presentation - Slideshow

TYRA 1 Targeting acquired resistance in oncology with purpose-built drugs May 2022 Disclaimers THIS PRESENTATION IS MADE PURSUANT TO SECTION 5(D) OF THE SECURITIES ACT OF 1933, as amended (the "Act"), and is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with Tyra Biosciences, Inc. (the "Company," "Tyra," "we" or "us") and determining whether such investors might have an interest in a securit ...